Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh

Jamiruddin, Mohd. Raeed; Haq, Ahsanul; Khondoker, Mohib Ullah; Ali, Tamanna; Ahmed, Firoz; Khandker, Shahad Saif; Jawad, Irfan; Hossain, Rubel; Ahmed, Sohel; Rahman, Sabita Rezwana; Mustafi, Mamun; Kaitsuka, Taku; Mie, Masayasu; Tomizawa, Kazuhito; Kobatake, Eiry; Haque, Mainul; Adnan, Nihad

doi:10.1080/14760584.2021.1977630

Cited by 14 publications

(7 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, it was found that in patients who had had COVID-19, the levels of total and virus neutralizing antibodies were significantly higher than in patients who had had no contact with SARS-CoV-2 antigens [ 69 ]. Similar results were obtained for the AstraZeneca vaccine [ 70 ].…”

Section: Vaccine Selection Approachessupporting

confidence: 86%

COVID-19 Vaccines: An Overview of Different Platforms

Kudlаy

Svistunov

2022

Bioengineering

View full text Add to dashboard Cite

Vaccination is one of the key strategies to stop the COVID-19 pandemic. This review aims to evaluate the current state of vaccine development and to determine the issues that merit additional research. We conducted a literature review of the development of COVID-19 vaccines, their effectiveness, and their use in special patient groups. To date, 140 vaccines are in clinical development. Vector, RNA, subunit, and inactivated vaccines, as well as DNA vaccines, have been approved for human use. Vector vaccines have been well studied prior to the COVID-19 pandemic; however, their long-term efficacy and approaches to scaling up their production remain questionable. The main challenge for RNA vaccines is to improve their stability during production, storage, and transportation. For inactivated vaccines, the key issue is to improve their immunogenicity and effectiveness. To date, it has been shown that the immunogenicity of COVID-19 vaccines directly correlates with their clinical efficacy. In view of the constant mutation, the emerging new SARS-CoV-2 variants have been shown to be able to partially escape post-vaccination immune response; however, most vaccines remain sufficiently effective regardless of the variant of the virus. One of the promising strategies to improve the effectiveness of vaccination, which is being studied, is the use of different platforms within a single vaccination course. Despite significant progress in the development and study of COVID-19 vaccines, there are many issues that require further research.

show abstract

Section: Vaccine Selection Approachessupporting

confidence: 86%

COVID-19 Vaccines: An Overview of Different Platforms

Kudlаy

Svistunov

2022

Bioengineering

View full text Add to dashboard Cite

show abstract

“…Seroconversion after vaccination indicates that protective immunity has been activated in the vaccinated host [243]. The rapid diagnostic test (RDT), enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and neutralization assay are the different types of serodiagnostic tests that can be employed to identify seroconversion, persistence, and longitudinal dynamics of both the neutralizing and non-neutralizing antibodies [186,[244][245][246][247][248][249][250][251]. Besides, serological testing is crucial for immuno-compromised or autoimmune patients, who generally have altered immune responses [252][253][254].…”

Section: Importance Of the Integration Of Diagnostic Assays Pre-and Post-vaccinationmentioning

confidence: 99%

A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues

Khandker¹,

Godman

Jawad

et al. 2021

Vaccines

Self Cite

View full text Add to dashboard Cite

COVID-19 vaccines are indispensable, with the number of cases and mortality still rising, and currently no medicines are routinely available for reducing morbidity and mortality, apart from dexamethasone, although others are being trialed and launched. To date, only a limited number of vaccines have been given emergency use authorization by the US Food and Drug Administration and the European Medicines Agency. There is a need to systematically review the existing vaccine candidates and investigate their safety, efficacy, immunogenicity, unwanted events, and limitations. The review was undertaken by searching online databases, i.e., Google Scholar, PubMed, and ScienceDirect, with finally 59 studies selected. Our findings showed several types of vaccine candidates with different strategies against SARS-CoV-2, including inactivated, mRNA-based, recombinant, and nanoparticle-based vaccines, are being developed and launched. We have compared these vaccines in terms of their efficacy, side effects, and seroconversion based on data reported in the literature. We found mRNA vaccines appeared to have better efficacy, and inactivated ones had fewer side effects and similar seroconversion in all types of vaccines. Overall, global variant surveillance and systematic tweaking of vaccines, coupled with the evaluation and administering vaccines with the same or different technology in successive doses along with homologous and heterologous prime-booster strategy, have become essential to impede the pandemic. Their effectiveness appreciably outweighs any concerns with any adverse events.

show abstract

“…This is possible because of the comparatively higher burden of natural infection in Delhi throughout the pandemic and later during the second wave. Moreover, there is growing recognition that even a single dose of COVID-19 vaccination post-infection induces a robust antibody response [ 24 , 25 ].…”

Section: Discussionmentioning

confidence: 99%

SARS-CoV-2 Seroprevalence in Delhi, India, During September-October 2021: A Population-Based Seroepidemiological Study

Sharma¹,

Basu²,

Mishra³

et al. 2022

Cureus

View full text Add to dashboard Cite

BackgroundA previous community-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serosurvey in Delhi in January 2021 reported a seroprevalence of 50.52%. We conducted a repeat serosurvey to obtain a recent estimate of the seroprevalence of IgG SARS-CoV-2 in the general population of Delhi, India. MethodsThis cross-sectional study was conducted from September 24 to October 14, 2021, in 274 wards of Delhi among 27,811 participants through a multistage sampling technique. ResultsThe crude seroprevalence was 89.5% (95% CI 89.1, 89.8), weight for age and sex was 88% (95% CI 87.6, 88.4), and after adjustment for assay performance was estimated as 97.5% (95% CI 97.0, 98.0). On adjusted analysis, the odds of seroconversion in the participants vaccinated with at least one dose of either COVID-19 vaccine (Covishield/Covaxin) was more than four times compared to the unvaccinated ones (aOR 4.2 (3.8, 4.6)). 86.8% of the seropositive individuals had a SARS-CoV-2 signal/cut-off ≥4.0 although it was significantly lower in the pediatric age group. Post-second wave (August to October 2021), on average there were daily 39 new COVID-19 cases and 0.44 deaths which during Omicron driven the third wave in January to March 2022 increased to daily 4,267 cases and 11.6 deaths. ConclusionA high prevalence of IgG antibodies against SARS-CoV-2 with likely higher antibody titres in the vaccinated compared to the unvaccinated groups with evidence of hybrid immunity in a majority of the population was protective against severe disease during transmission of subsequent omicron variants.

show abstract

Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh

Cited by 14 publications

References 53 publications

COVID-19 Vaccines: An Overview of Different Platforms

COVID-19 Vaccines: An Overview of Different Platforms

A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues

SARS-CoV-2 Seroprevalence in Delhi, India, During September-October 2021: A Population-Based Seroepidemiological Study

Contact Info

Product

Resources

About